XML 70 R53.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2022
Aug. 31, 2018
May 31, 2018
Mar. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2018
Dec. 31, 2016
Other Commitments [Line Items]                  
Gain (loss) on strategic investment         $ 3,542 $ 2,329 $ (997)    
Restricted cash         5,770 5,770 5,770    
Corporate Credit Card Program | Letter of Credit                  
Other Commitments [Line Items]                  
Restricted cash                 $ 2,000
Fleet Program | Letter of Credit                  
Other Commitments [Line Items]                  
Restricted cash         400        
Other assets                  
Other Commitments [Line Items]                  
Aggregate carrying amount of strategic equity investment         7,200 3,600      
Other expense                  
Other Commitments [Line Items]                  
Gain (loss) on strategic investment         3,500 2,300 1,000    
Stoke Therapeutics, Inc. | Research and development                  
Other Commitments [Line Items]                  
Mile stone payments payable         907,500        
Upfront consideration and transaction costs       $ 60,000          
Cost splits description For the SYNGAP1 program, the two companies will jointly share global research, development and commercialization responsibilities and share 50/50 in all worldwide costs and future profits.                
License Agreements                  
Other Commitments [Line Items]                  
Upfront payment         8,700 $ 11,000 $ 72,700    
Milestone payment may be due         40,000        
License Agreements | North America                  
Other Commitments [Line Items]                  
Mile stone payments payable   $ 40,000              
License Agreements | Neuren | North America                  
Other Commitments [Line Items]                  
Upfront license fee   10,000              
License Agreements | Neuren | Research and development | North America                  
Other Commitments [Line Items]                  
Upfront payment               $ 10,000  
Exclusivity Deed | Neuren                  
Other Commitments [Line Items]                  
Aggregate carrying amount of strategic equity investment     $ 3,100            
Shares subscribed     1,330,000            
Exclusivity Deed | Neuren | Sales, general and administrative                  
Other Commitments [Line Items]                  
Payments for exclusive right     $ 900            
Maximum                  
Other Commitments [Line Items]                  
Mile stone payments payable         $ 1,600,000        
Maximum | License Agreements | Neuren | North America                  
Other Commitments [Line Items]                  
Mile stone payments payable   $ 455,000